Source:http://linkedlifedata.com/resource/pubmed/id/21393136
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
4
|
| pubmed:dateCreated |
2011-3-15
|
| pubmed:abstractText |
Maraviroc is the first licensed chemokine co-receptor 5 (CCR5) co-receptor antagonist in clinical practice. It is currently being used in patients harbouring exclusively CCR5-tropic virus. The objective of the study was to investigate the impact of maraviroc on viruses with different co-receptor preferences in a patient with a dual/mixed (D/M) infection.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Apr
|
| pubmed:issn |
1460-2091
|
| pubmed:author | |
| pubmed:issnType |
Electronic
|
| pubmed:volume |
66
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
890-5
|
| pubmed:meshHeading |
pubmed-meshheading:21393136-Anti-HIV Agents,
pubmed-meshheading:21393136-Cell Line,
pubmed-meshheading:21393136-Cyclohexanes,
pubmed-meshheading:21393136-Genotype,
pubmed-meshheading:21393136-HIV Infections,
pubmed-meshheading:21393136-HIV-1,
pubmed-meshheading:21393136-Humans,
pubmed-meshheading:21393136-Male,
pubmed-meshheading:21393136-Middle Aged,
pubmed-meshheading:21393136-Treatment Outcome,
pubmed-meshheading:21393136-Triazoles,
pubmed-meshheading:21393136-Viral Tropism
|
| pubmed:year |
2011
|
| pubmed:articleTitle |
Maraviroc is able to inhibit dual-R5 viruses in a dual/mixed HIV-1-infected patient.
|
| pubmed:affiliation |
Department of Virology, Medical Microbiology, University Medical Center Utrecht, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands.
|
| pubmed:publicationType |
Journal Article,
Case Reports,
Research Support, Non-U.S. Gov't
|